Olema gives small update to breast cancer drug at center of layoffs, 2021 data leak
Olema Pharmaceuticals is out with more data on its investigational breast cancer drug, for which it shed 25% of its workforce two months ago to keep funding its research.
The San Francisco-based biotech said its drug, which was at the center of a “falsified” data leak in November 2021, was “well-tolerated” and had no dose-limiting toxicities when combined with Pfizer’s Ibrance. Olema is testing OP-1250 in patients with ER+/HER2- metastatic breast cancer, and the safety and tolerability update comes from a look at 29 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.